EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Impact of epigenetic reprogramming on antitumor immune responses in glioma

Brandon L McClellan, Santiago Haase, Felipe J Nunez, Mahmoud S Alghamri, Ali A Dabaja, Pedro R Lowenstein, Maria G Castro

Journal of Clinical Investigation · 2023

DOI: 10.1172/jci163450 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, 2023. Verfasst von Brandon L McClellan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery and. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic remodeling is a molecular hallmark of gliomas, and it has been identified as a key mediator of glioma progression. Epigenetic dysregulation contributes to gliomagenesis, tumor progression, and responses to immunotherapies, as well as determining clinical features. This epigenetic remodeling includes changes in histone modifications, chromatin structure, and DNA methylation, all of which are driven by mutations in genes such as histone 3 genes (H3C1 and H3F3A), isocitrate dehydrogenase 1/2 (IDH1/2), α-thalassemia/mental retardation, X-linked (ATRX), and additional chromatin remodelers. Although much of the initial research primarily identified how the epigenetic aberrations impacted glioma progression by solely examining the glioma cells, recent studies have aimed at establishing the role of epigenetic alterations in shaping the tumor microenvironment (TME). In this review, we discuss the mechanisms by which these epigenetic phenomena in glioma remodel the TME and how current therapies targeting epigenetic dysregulation affect the glioma immune response and therapeutic outcomes. Understanding the link between epigenetic remodeling and the glioma TME provides insights into the implementation of epigenetic-targeting therapies to improve the antitumor immune response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGliomaHumansMutationChromatinIsocitrate DehydrogenaseEpigenesis, GeneticTumor Microenvironment

Substanzen

ChromatinIsocitrate Dehydrogenase

Autor:innen und Institutionen

  • Department of Neurosurgery and.
  • Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Accenture-Argentina, Autonomous City of Buenos Aires (CABA), Argentina.
  • Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
  • Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

McClellan, B. L., Haase, S., Nunez, F. J., Alghamri, M. S., Dabaja, A. A., Lowenstein, P. R., & Castro, M. G. (2023). Impact of epigenetic reprogramming on antitumor immune responses in glioma. Journal of Clinical Investigation. https://doi.org/10.1172/jci163450

Vancouver

McClellan BL, Haase S, Nunez FJ, Alghamri MS, Dabaja AA, Lowenstein PR, et al. Impact of epigenetic reprogramming on antitumor immune responses in glioma. Journal of Clinical Investigation. 2023. doi:10.1172/jci163450

BibTeX
@article{McClellan2023,
  author = {McClellan, Brandon L and Haase, Santiago and Nunez, Felipe J and Alghamri, Mahmoud S and Dabaja, Ali A and Lowenstein, Pedro R and Castro, Maria G},
  title = {Impact of epigenetic reprogramming on antitumor immune responses in glioma},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  doi = {10.1172/jci163450}
}
Kostenlos starten →